Treatment with human insulin (recombinant DNA) in diabetic subjects pretreated with pork or beef insulin: first results of a multicenter study.
In two double-blind studies 66 insulin-dependent diabetic subjects pretreated with pork insulin were changed to human insulin (recombinant DNA) or a purified pork insulin preparation (regular and NPH insulin). Sixty-five patients previously pretreated with beef insulin were transferred, in a randomized, double-blind fashion, to human insulin and purified beef insulin of the same preparations (regular and NPH insulin). Patients' metabolic control, as demonstrated by fasting and 1-h postprandial blood glucose, HbA1c, and daily insulin dosage, over 4 mo was unchanged in our four groups compared with the values before changing insulin preparation. No severe hypoglycemic attacks or skin reactions were reported.
D000328:Adult; D000368:Aged; D000818:Animals; D001786:Blood Glucose; D002417:Cattle; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D007336:Insulin, Isophane / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D013552:Swine
D001786:Blood Glucose; D007328:Insulin; D011994:Recombinant Proteins; D007336:Insulin, Isophane